836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

Erika Hamilton, Minal Barve, Anthony W. Tolcher, Joseph Buscema, Kyriakos P. Papadopoulos, Corrine Zarwan, Charles Anderson, Deborah B. Doroshow, Dee Dee Wang, D. Huebner, Valerie M. Jansen, Donna Jarlenski, Rebecca Mosher, Jonathan L. Kaufman, Kathleen N. Moore, Debra L. Richardson